Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel

Walter J. McConathy, Maya P. Nair, Sulabha Paranjape, Linda Mooberry, Andras G. Lacko

Research output: Contribution to journalArticlepeer-review

118 Scopus citations


Reconstituted (synthetic) high-density lipoprotein particles carrying paclitaxel (rHDL/PTX) were prepared with substantially higher PTX content than reported earlier. The rHDL/PTX complexes seemed to be primarily spherical nanoparticles when examined via electron microscopy, with a constant composition, molecular weight and exceptional stability even after ultracentrifugation and storage for up to 6 months. The rHDL/PTX nanoparticles had superior cytotoxicity against several cancer cell lines (MCF7, DU145, OV1063 and OVCAR-3), the half maximal inhibitory concentration (IC50) having been found to be 5-20 times lower than that of the free drug. Studies with mice showed that the rHDL/PTX nanoparticles were substantially better tolerated than the corresponding dosages of either Taxol or Abraxane.

Original languageEnglish
Pages (from-to)183-188
Number of pages6
JournalAnti-Cancer Drugs
Issue number2
StatePublished - Feb 2008


  • Chemotherapy
  • Drug delivery
  • Nanoparticles
  • Reconstituted (synthetic) high-density lipoprotein


Dive into the research topics of 'Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel'. Together they form a unique fingerprint.

Cite this